IRVINE, Calif.--(BUSINESS WIRE)--To support increasing demand globally for COVID-19 testing, BioDot has compressed production times for most new lateral flow dispensing platforms from months to four ...
BioDot Inc. of Irvine had plans to scale in 2020. It didn’t anticipate a global pandemic, which drove demand higher than ever before for its ultra low-volume dispensers that are used to dispense ...
Biodot, which started operations in 1994, manufactures automated ultra-low-volume fluid dispensing systems for labs that make antibody or serology tests. These tests are indicators of immune responses ...
CAMBRIDGE, Ont. — ATS Automation Tooling Systems Inc. has signed a deal to buy U.S. company BioDot Inc., a manufacturer of automated fluid dispensing systems, for $106 million. California-based BioDot ...
ATS entered into a definitive agreement and announced its intention to acquire BioDot on April 14, 2021. CAMBRIDGE — On June 1, ATS Automation Tooling Systems Inc., an automation solutions provider, ...
BioDot Ltd has announced that it has relocated its European headquarters. The relocation expands BioDot’s sales and support capabilities in Europe. Andrew Sweet, BioDot Ltd's Managing Director, ...
Artemis Capital Partners has acquired Irvine, California-based BioDot Inc, a maker of automated ultralow volume fluid dispensing systems. No financial terms were disclosed. IRVINE, Calif., April 9, ...
BioDot and JOT Automation Enter a Co-marketing and Sales Agreement for BioDot to promote and support JOT's lateral flow assembly systems. Andrew Sweet states, "BioDot has been looking to complete its ...
The need for accessible, convenient and rapid testing over the course of the pandemic pushed the FDA to temporarily approve over-the-counter COVID-19 tests. That’s one result of the past year that ...
BioDot, Inc., a supplier of nanoliter dispensing systems has entered a strategic alliance with Berlin-based Scienion AG, a picoliter liquid handling specialist, to accelerate the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results